EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Economic analysis of hyperbaric oxygen therapy for the treatment of ischaemic diabetic foot ulcers

Robin J Brouwer, Nick S van Reijen, Marcel G Dijkgraaf, Rigo Hoencamp, Mark Jw Koelemay, Robert A van Hulst, Dirk T Ubbink

Diving and Hyperbaric Medicine Journal · 20.12.2024 · 54 (4) · 265-274

DOI: 10.28920/dhm54.4.265-274 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diving and Hyperbaric Medicine Journal, online erschienen am 20.12.2024. Verfasst von Robin J Brouwer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Anaesthesiology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Hyperbaric Oxygenation, Diabetic Foot, Cost-Benefit Analysis, Quality-Adjusted Life Years. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The aim was to determine the cost-effectiveness and cost-utility of additional hyperbaric oxygen therapy (HBOT) compared to standard care (SC) for ischaemic diabetic foot ulcers (DFUs) regarding limb salvage and health status.

Methods

An economic analysis was conducted, comprising cost-effectiveness and cost-utility analyses, with a 12-month time horizon, using data from the DAMO2CLES multicentre randomised clinical trial. Cost-effectiveness was defined as cost per limb saved and cost-utility as cost per quality-adjusted life year (QALY). The difference in cost effectiveness between HBOT+SC and SC alone was determined via an incremental cost-effectiveness ratio (ICER).

Results

One-hundred and twenty patients were included, with 60 allocated to HBOT+SC and 60 to SC. No significant cost difference was found in the intention-to-treat analysis: €3,791 (bias corrected and accelerated [BCA] 95% CI, €3,556 –€-11,138). Cost per limb saved showed an ICER of €37,912 (BCA 95% CI €-112,188–€1,063,561) for HBOT+SC vs. SC. There was no significant difference in mean QALYs: 0.54 for HBOT+SC vs. 0.56 for SC alone (-0.02; BCA 95% CI -0.11–0.08). This resulted in a cost-utility of minus €227,035 (BCA 95% CI €-361,569,550–€-52,588) per QALY. Subgroup analysis for Wagner stages III/IV showed an ICER of €19,005 (BCA 95%CI, €-18,487–€264,334) while HBOT did not show any benefit for Wagner stage II.

Conclusions

HBOT as an adjunct to SC showed no significant differences in costs and effectiveness for patients with DFUs regarding limb salvage and health status. However, for patients with Wagner stage III/IV ischaemic DFUs there was a trend towards better effectiveness and cost-effectiveness.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hyperbaric OxygenationDiabetic FootCost-Benefit AnalysisQuality-Adjusted Life YearsLimb SalvageHumansMaleFemaleAgedMiddle AgedIschemiaStandard of CareHealth Status

Stichwörter der Autor:innen

Cost-effectivenessPeripheral arterial occlusive diseaseWound healing

Autor:innen und Institutionen

  • Department of Anaesthesiology, Amsterdam UMC, Location AMC, Amsterdam, The Netherlands.
  • Department of Surgery, Alrijne Hospital, Leiderdorp, The Netherlands.
  • Corresponding author: Dr Robin J Brouwer, Department of Anaesthesiology, Amsterdam University Medical Centers, Meibergdreef 9, 1105AZ, Amsterdam, The Netherlands, rjbrouwer@alrijne.nl.
  • Department of Surgery, Amsterdam UMC, Location AMC, Amsterdam Cardiovascular Sciences, Amsterdam, The Netherlands.
  • Department of Clinical Epidemiology, Biostatistics and Bioinformatics, Amsterdam UMC, Location AMC, Amsterdam, The Netherland.
  • Department of Surgery, Leiden University Medical Center, Leiden, The Netherlands.

Zitieren

APA

Brouwer, R. J., van Reijen, N. S., Dijkgraaf, M. G., Hoencamp, R., Koelemay, M. J., van Hulst, R. A., & Ubbink, D. T. (2024). Economic analysis of hyperbaric oxygen therapy for the treatment of ischaemic diabetic foot ulcers. Diving and Hyperbaric Medicine Journal, 54(4), 265-274. https://doi.org/10.28920/dhm54.4.265-274

Vancouver

Brouwer RJ, van Reijen NS, Dijkgraaf MG, Hoencamp R, Koelemay MJ, van Hulst RA, et al. Economic analysis of hyperbaric oxygen therapy for the treatment of ischaemic diabetic foot ulcers. Diving and Hyperbaric Medicine Journal. 2024;54(4):265-274. doi:10.28920/dhm54.4.265-274

BibTeX
@article{Brouwer2024,
  author = {Brouwer, Robin J and van Reijen, Nick S and Dijkgraaf, Marcel G and Hoencamp, Rigo and Koelemay, Mark Jw and van Hulst, Robert A and Ubbink, Dirk T},
  title = {Economic analysis of hyperbaric oxygen therapy for the treatment of ischaemic diabetic foot ulcers},
  journal = {Diving and Hyperbaric Medicine Journal},
  year = {2024},
  volume = {54},
  number = {4},
  pages = {265--274},
  doi = {10.28920/dhm54.4.265-274}
}
Kostenlos starten →